A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Please provide your email address to receive an email when new articles are posted on . Sustained DMARD-free remission “does not seem attainable” for patients with RA requiring biological DMARDs, but ...

Please provide your email address to receive an email when new articles are posted on . Despite guidelines recommending early and aggressive therapy in RA, disease-modifying antirheumatic drug ...

The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...

A scoping review published in Arthritis Care & Research compares existing recommendations for the use of disease-modifying anti-rheumatic drugs (DMARDs) in pregnancy and reproductive health for women ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Nonadherence to DMARDs in RA varies widely, with rates from 1.5% to 100% across different studies and DMARD classes. The review identified 31 unique nonadherence measures, with indirect methods like ...

Only a decade ago, prior to the availability of anti-TNF agents and other BRMs, most patients with RA were treated with MTX and other DMARDs. Although many patients with RA responded relatively well ...

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with ...

Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...